Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Time to Sell Portola?


Portola Pharmaceuticals' (NASDAQ: PTLA) stock recently jumped 45% on the news that it won its first FDA approval.

In this segment of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain why investors might want to stick with the company rather than cash out now, and some important things to remember about investing in any biotech.

A full transcript follows the video.

Continue reading


Source: Fool.com

Like: 0
Share

Comments